Pliant Therapeutics (PLRX)
PLRX · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Fibrosissrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 1
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. — Nat Commun (2026) PMID 42538332
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. — Cancer (2026) PMID 42487497
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Pliant Therapeutics.
Full PLRX Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.